Cancer Treatment Stocks: Three Leading Players Riding the Innovation Wave

The global fight against cancer is entering a transformative phase. With the American Cancer Society projecting approximately 2.04 million new cancer diagnoses in the United States alone during 2025, alongside more than 618,000 cancer-related deaths, the imperative for effective treatment solutions has never been clearer. This growing patient population, combined with aging demographics worldwide and lifestyle-related risk factors, is fueling unprecedented investment in breakthrough therapies. For investors seeking exposure to this secular growth trend, cancer treatment stocks have emerged as compelling opportunities, particularly those with innovative pipelines addressing the latest scientific advances.

The traditional cancer care landscape is being fundamentally transformed. Immunotherapies, targeted treatments, and personalized medicine are revolutionizing patient outcomes, extending far beyond conventional chemotherapy and radiation. Checkpoint inhibitors, CAR-T therapies, therapeutic vaccines, and oncolytic viruses represent a new generation of treatments that harness the body’s own immune system to combat tumors. Meanwhile, targeted therapies are improving precision by focusing on specific genetic mutations, while cancer vaccines mark a meaningful leap in personalized oncology. Supporting these advances, technologies like genomic sequencing, artificial intelligence, and machine learning are accelerating biomarker discovery and enabling earlier diagnosis—factors that promise not only improved survival rates but also enhanced quality of life across multiple cancer types.

Recognizing these opportunities, global pharmaceutical giants are aggressively reshaping their portfolios. Novartis, AstraZeneca, J&J, Pfizer, AbbVie, Merck, Bristol Myers Squibb, and Eli Lilly are all strengthening their oncology arsenals with antibody-drug conjugates, bispecific antibodies, and next-generation immuno-oncology programs. Smaller biotech firms, meanwhile, continue driving the innovation frontier through partnerships, licensing deals, and strategic acquisitions. This dynamic environment suggests that cancer stocks positioned at the intersection of clinical progress and commercial opportunity remain among the most attractive healthcare investments for long-term portfolios.

J&J: Leveraging Established Dominance to Expand Cancer Treatment Reach

Johnson & Johnson stands as a cornerstone player in the global cancer treatment landscape, with oncology representing approximately 27% of total company revenues. The division’s performance has been particularly robust: in the first nine months of 2025, oncology sales climbed 20.6% on an operational basis to $18.52 billion, driven by both market expansion and gaining market share in key therapeutic areas.

The company’s established cancer drugs continue delivering strong commercial performance. Multiple myeloma treatment Darzalex and prostate cancer drug Erleada remain cornerstone products, but J&J has successfully launched a wave of newer therapies that are driving incremental growth. Carvykti, Tecvayli, Talvey, Rybrevant, and Lazcluze have all demonstrated strong market uptake following their launches, signaling physician and patient confidence in J&J’s latest offerings.

What distinguishes J&J’s position, however, is the momentum building in its development pipeline. During the past two years, the company achieved eight proof-of-concept readouts that advanced candidates into late-stage pivotal trials across multiple indications. Particularly noteworthy are promising developments in colorectal and head and neck cancers—areas representing significant patient populations with limited current options. If these candidates successfully navigate the regulatory pathway, they could substantially accelerate J&J’s oncology growth trajectory over the coming years.

The company is also augmenting its cancer treatment portfolio through strategic M&A. A definitive agreement to acquire Halda Therapeutics signals J&J’s commitment to strengthening its presence in prostate cancer, where it already commands significant market share through established drugs like Zytiga and Akeega. J&J has explicitly guided that oncology sales will reach $50 billion by the end of this decade—a target that underscores management’s confidence in the division’s growth potential. With a Zacks Rank of #2 (Buy), J&J represents a diversified way to play cancer treatment innovation at scale.

ImmunityBio and Foghorn: Innovative Platforms Addressing Unmet Cancer Needs

While large-cap pharmaceutical companies offer scale and breadth, smaller biotech firms frequently offer concentrated bets on transformative technologies. ImmunityBio exemplifies this dynamic. The company’s lead candidate, Anktiva, received FDA approval in April 2024 for combination use with BCG to treat BCG-unresponsive non-muscle invasive bladder cancer. This represented a meaningful breakthrough, as Anktiva represents the first-in-class IL-15 agonist designed for this specific indication.

Commercial uptake has been encouraging. Year-to-date sales of Anktiva have reached $74.7 million, with impressive volume growth of 467%—suggesting robust physician adoption and patient demand. The medication is currently under regulatory review in the European Union. Indeed, last week the European Medicines Agency recommended granting conditional marketing authorization in the EU, potentially unlocking another significant market for the cancer treatment stock.

Beyond bladder cancer, ImmunityBio is expanding Anktiva’s scope through clinical studies evaluating both monotherapy and combination approaches across several additional cancer indications, including NSCLC, glioblastoma, and non-Hodgkin lymphoma. In early NSCLC studies, Anktiva has shown potential to reverse lymphopenia—a critical limiting factor in cancer patient outcomes—while extending overall survival. Glioblastoma studies have demonstrated strong disease control data. With a Zacks Rank of #2, ImmunityBio’s focused pipeline and successful execution position it as a compelling choice among cancer treatment stocks for investors seeking exposure to emerging immunotherapies.

Foghorn Therapeutics approaches cancer treatment through a distinctly different lens: the chromatin regulatory system. Leveraging its proprietary Gene Traffic Control platform, the company is developing precision therapies targeting genetically driven cancer vulnerabilities. Most notably, Foghorn has partnered with Eli Lilly to co-develop and co-commercialize its selective SMARCA2 oncology program—a collaboration that validates Foghorn’s technological approach while providing substantial resources for advancement.

The lead candidate from this partnership, FHD-909, represents the first-in-class SMARCA2 inhibitor currently advancing through a Phase I dose escalation study for SMARCA4-mutated cancers, with particular focus on NSCLC. Initial clinical data is anticipated in 2026. Preclinical work has demonstrated that FHD-909 achieves significant anti-tumor activity across multiple SMARCA4-mutant lung tumor models, and there is substantial unmet medical need among SMARCA4 mutant NSCLC patients—a factor that could drive rapid uptake should clinical trials support its efficacy profile.

Looking beyond FHD-909, Foghorn’s wholly-owned pipeline includes first-in-class selective degrader programs targeting CBP, EP300, and ARID1B genes. These additional programs suggest a company with multiple shots on goal within the precision oncology space. Foghorn’s Zacks Rank of #2 reflects the potential for its innovative cancer treatment platform to generate meaningful shareholder returns.

Investment Perspective: Why Cancer Stocks Remain Compelling

The convergence of rising cancer incidence, rapid treatment innovation, and substantial unmet medical needs creates a compelling investment backdrop for cancer stocks. The three companies highlighted—J&J, ImmunityBio, and Foghorn Therapeutics—represent different entry points into this secular trend. J&J provides large-cap diversification with proven commercial execution; ImmunityBio delivers focused immunotherapy exposure with early commercial traction; Foghorn offers precision oncology optionality through its proprietary platform approach.

Supportive factors for cancer stocks include favorable reimbursement dynamics, regulatory encouragement of innovative therapies as evidenced by breakthrough designations and accelerated approvals, and the tangible expansion of treatment options extending patient life and improving quality of life. As pharmaceutical companies and investors alike continue recognizing oncology’s position as one of the most durable segments within global healthcare, cancer treatment stocks remain worthy of consideration within diversified long-term investment portfolios.